ArticleJournal of clinical microbiology2004
Use of the MagNA pure LC automated nucleic acid extraction system followed by real-time reverse transcription-PCR for ultrasensitive quantitation of hepatitis C virus RNA.
Article in Journal of clinical microbiology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 49 citations in OpenAlex.
- Pooling nasopharyngeal/throat swab specimens to increase testing capacity for influenza viruses by PCR.Journal of clinical microbiology · 2012Article
- Naturally occurring genotype 2b/1a hepatitis C virus in the United States.Virology journal · 2011Article
- Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies.Journal of virology · 2008Article
- Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity.Journal of virology · 2008Article
- Effect of cell polarization on hepatitis C virus entry.Journal of virology · 2008Article
- Relationships between hepatitis C virus replication and CXCL-8 production in vitro.Journal of virology · 2006Article
- Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection.Virology journal · 2006Article
- Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.Journal of clinical microbiology · 2006Article
- Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C disease severity in vivo.Journal of virology · 2006Article
- Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells.Virology journal · 2005Article
- Automated extraction of viral-pathogen RNA and DNA for high-throughput quantitative real-time PCR.Journal of clinical microbiology · 2005Article
- Primer sequence modification enhances hepatitis C virus genotype coverage.Journal of clinical microbiology · 2005Article
- Detection and monitoring of virus infections by real-time PCR.Molecular aspects of medicineReview
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is an increasing health problem worldwide. Quantitative assays for HCV viral load are valuable in predicting response to therapy and for following treatment efficacy. Unfortunately, most quantitative tests for HCV RNA are limited by poor sensitivity. We have developed a convenient, highly sensitive real-time reverse transcription-PCR assay for HCV RNA. The assay amplifies a portion of the 5' untranslated region of HCV, which is then quantitated using the TaqMan 7700 detection system. Extraction of viral RNA for our assay is fully automated with the MagNA Pure LC extraction system (Roche). Our assay has a 100% detection rate for samples containing 50 IU of HCV RNA/ml and is linear up to viral loads of at least 10(9) IU/ml. The assay detects genotypes 1a, 2a, and 3a with equal efficiency. Quantitative results by our assay correlate well with HCV viral load as determined by the Bayer VERSANT HCV RNA 3.0 bDNA assay. In clinical use, our assay is highly reproducible, with high and low control specimens showing a coefficient of variation for the logarithmic result of 2.8 and 7.0%, respectively. The combination of reproducibility, extreme sensitivity, and ease of performance makes this assay an attractive option for routine HCV viral load testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.